← Leaderboards
Michael Chorny
Children'S Hosp Of Philadelphia
$5,184,479
Attributed
$7,847,964
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2012–24$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,847,964 · 5
By mechanism
R01$6,901,964 · 3
R21$946,000 · 2
Top collaborators
- Garrett M Brodeur5 shared
- Masahiro Iwamoto5 shared
- David Brian Frank2 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Ilia Fishbein$3,426,991
- Kelly C Goldsmith$1,560,816
- Stanley Joseph Stachelek$1,791,630
- Robert J Levy$36,673,646
- Julie R Park$6,704,912
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseGrowthToxic EffectBasePharmaceutical PreparationsKineticsUptakePharmacologyPreventTargeted DeliveryAdverse EffectsEffective TherapyDrug Delivery SystemsProdrugsPharmacotherapyDesignTissuesMediatingMorphometryIn VitroIn VivoSiteCellsRepaired
Grant awards (19)
Prodrugs targeting norepinephrine transporter for dual-selective therapy of refractory neuroblastoma$591,818
R01 · FY2024 · CA · contact PI
Prodrugs targeting norepinephrine transporter for dual-selective therapy of refractory neuroblastoma$610,508
R01 · FY2023 · CA · contact PI
Prodrugs targeting norepinephrine transporter for dual-selective therapy of refractory neuroblastoma$610,508
R01 · FY2022 · CA · contact PI
Local Control of endochondral ossification by retinoid-loaded nano-particles$352,464
R01 · FY2022 · AR
Multimeric prodrugs for pulmonary hypertension therapy$264,000
R21 · FY2022 · HL · contact PI
Prodrugs targeting norepinephrine transporter for dual-selective therapy of refractory neuroblastoma$622,966
R01 · FY2021 · CA · contact PI
Local Control of endochondral ossification by retinoid-loaded nano-particles$345,343
R01 · FY2021 · AR
Multimeric prodrugs for pulmonary hypertension therapy$220,000
R21 · FY2021 · HL · contact PI
Prodrugs targeting norepinephrine transporter for dual-selective therapy of refractory neuroblastoma$622,966
R01 · FY2020 · CA · contact PI
Local Control of endochondral ossification by retinoid-loaded nano-particles$356,024
R01 · FY2020 · AR
Local Control of endochondral ossification by retinoid-loaded nano-particles$359,192
R01 · FY2019 · AR
Local Control of endochondral ossification by retinoid-loaded nano-particles$371,182
R01 · FY2018 · AR
Integrated drug-in-cell therapy of in-stent restenosis$252,000
R21 · FY2017 · HL · contact PI
Uniform field controlled magnetic cell targeting to stents$418,750
R01 · FY2016 · HL · contact PI
Integrated drug-in-cell therapy of in-stent restenosis$210,000
R21 · FY2016 · HL · contact PI
Uniform field controlled magnetic cell targeting to stents$412,468
R01 · FY2015 · HL · contact PI
Uniform field controlled magnetic cell targeting to stents$410,375
R01 · FY2014 · HL · contact PI
Uniform field controlled magnetic cell targeting to stents$398,650
R01 · FY2013 · HL · contact PI
Uniform field controlled magnetic cell targeting to stents$418,750
R01 · FY2012 · HL · contact PI